FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387455035> ?p ?o ?g. }

• W4387455035 endingPage "8" @default.
• W4387455035 startingPage "1" @default.
• W4387455035 abstract "The growing prevalence of dementia makes it important for us to better understand its pathophysiology and treatment modalities, to improve the quality of life of patients and caregivers. Alzheimer’s disease (AD), a neurodegenerative disease, is the most common form of amnestic dementia in the geriatric population. Pathophysiology of AD is widely attributed to aggregation of amyloid-beta (Aβ) plaques and hyperphosphorylation of tau proteins. Initial treatment modalities aimed to increase brain perfusion in a non-specific manner. Subsequent therapy focused on rectifying neurotransmitter imbalance in the brain. Newer drugs modify the progression of the disease by acting against aggregated Aβ plaques. However, not all drugs used in therapy of AD have been granted approval by the United States Food and Drug Administration (FDA). This review categorizes and summarizes the FDA-approved drugs in the treatment of AD in a manner that would make it a convenient reference for researchers and practicing physicians alike. Drugs that mitigate symptoms of dementia may be categorized into mitigators of Behavioral and Psychological Symptoms of Dementia (BPSD), and mitigators of cognitive decline. BPSD mitigators include brexpiprazole, an atypical antipsychotic with a once-daily dosage suited to treat agitation in dementia patients, and suvorexant, an orexin receptor antagonist used to treat sleep disturbances. Cognitive decline mitigators include cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine and glutamate inhibitors such as memantine. Donepezil is the most commonly prescribed drug. It is cheap, well-tolerated, and may be prescribed orally once daily, or as a transdermal patch once weekly. It increases ACh levels, enhances oligodendrocyte differentiation and also protects against Aβ toxicity. However, regular cardiac monitoring is required due to reports of cardiac conduction side effects. Rivastigmine requires a twice-daily oral dosage or once-daily replacement of transdermal patch. It has fewer cardiac side effects than donepezil, but local application-site reactions have been noted. Galantamine, in addition to improving cognitive symptoms in a short span of time, also delays the development of BPSDs and has minimal drug-drug interactions by virtue of having multiple metabolic pathways. However, cardiac conduction disturbances must be closely monitored for. Memantine, a glutamate regulator, acts as an anti-Parkinsonian agent and an antidepressant, in addition to improving cognition and neuroprotection, and requires a once-daily dosage in the form of immediate-release or sustained-release oral tablets. Disease-modifying drugs such as aducanumab and lecanemab reduce the Aβ burden. Both act by binding with fibrillary conformations of Aβ plaques in the brain. These drugs have a risk of causing amyloid-related imaging abnormalities, especially in persons with ApoE4 gene. Aducanumab is administered once every 4 weeks and lecanemab once every 2 weeks. The decision on the choice of the drug must be made after considering the availability of drug, compliance of patient (once-daily vs. multiple doses daily), cost, specific comorbidities, and the risk-benefit ratio for the particular patient. Other non-pharmacological treatment modalities must also be adopted to have a holistic approach toward the treatment of AD." @default.
• W4387455035 created "2023-10-10" @default.
• W4387455035 creator A5021501440 @default.
• W4387455035 creator A5048775708 @default.
• W4387455035 creator A5052689417 @default.
• W4387455035 creator A5054535747 @default.
• W4387455035 creator A5062910781 @default.
• W4387455035 creator A5072859029 @default.
• W4387455035 creator A5073638406 @default.
• W4387455035 creator A5086569685 @default.
• W4387455035 creator A5087271386 @default.
• W4387455035 date "2023-10-07" @default.
• W4387455035 modified "2023-10-11" @default.
• W4387455035 title "Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs" @default.
• W4387455035 cites W1968338902 @default.
• W4387455035 cites W1971057491 @default.
• W4387455035 cites W1973366052 @default.
• W4387455035 cites W1974390938 @default.
• W4387455035 cites W1985528178 @default.
• W4387455035 cites W1994067502 @default.
• W4387455035 cites W2001206572 @default.
• W4387455035 cites W2003439867 @default.
• W4387455035 cites W2009297217 @default.
• W4387455035 cites W2016149437 @default.
• W4387455035 cites W2019924732 @default.
• W4387455035 cites W2034596923 @default.
• W4387455035 cites W2045562525 @default.
• W4387455035 cites W2049771698 @default.
• W4387455035 cites W2050556307 @default.
• W4387455035 cites W2054106674 @default.
• W4387455035 cites W2064721530 @default.
• W4387455035 cites W2067656054 @default.
• W4387455035 cites W2088417013 @default.
• W4387455035 cites W2091425658 @default.
• W4387455035 cites W2093345349 @default.
• W4387455035 cites W2108216694 @default.
• W4387455035 cites W2120296399 @default.
• W4387455035 cites W2142797329 @default.
• W4387455035 cites W2153790456 @default.
• W4387455035 cites W2154259512 @default.
• W4387455035 cites W2160552877 @default.
• W4387455035 cites W2288040218 @default.
• W4387455035 cites W2442715208 @default.
• W4387455035 cites W2463733761 @default.
• W4387455035 cites W2783328454 @default.
• W4387455035 cites W2802724927 @default.
• W4387455035 cites W2885800496 @default.
• W4387455035 cites W2923992900 @default.
• W4387455035 cites W2978677315 @default.
• W4387455035 cites W2988702876 @default.
• W4387455035 cites W2992893037 @default.
• W4387455035 cites W2999676104 @default.
• W4387455035 cites W3191999594 @default.
• W4387455035 cites W3201901176 @default.
• W4387455035 cites W3204222713 @default.
• W4387455035 cites W3208101326 @default.
• W4387455035 cites W4206055706 @default.
• W4387455035 cites W4210987525 @default.
• W4387455035 cites W4220730266 @default.
• W4387455035 cites W4284970070 @default.
• W4387455035 cites W4288428132 @default.
• W4387455035 cites W4309479679 @default.
• W4387455035 cites W4310461604 @default.
• W4387455035 cites W4312087441 @default.
• W4387455035 cites W4312128797 @default.
• W4387455035 cites W4328023305 @default.
• W4387455035 doi "https://doi.org/10.25259/jnrp_356_2023" @default.
• W4387455035 hasPublicationYear "2023" @default.
• W4387455035 type Work @default.
• W4387455035 citedByCount "0" @default.
• W4387455035 crossrefType "journal-article" @default.
• W4387455035 hasAuthorship W4387455035A5021501440 @default.
• W4387455035 hasAuthorship W4387455035A5048775708 @default.
• W4387455035 hasAuthorship W4387455035A5052689417 @default.
• W4387455035 hasAuthorship W4387455035A5054535747 @default.
• W4387455035 hasAuthorship W4387455035A5062910781 @default.
• W4387455035 hasAuthorship W4387455035A5072859029 @default.
• W4387455035 hasAuthorship W4387455035A5073638406 @default.
• W4387455035 hasAuthorship W4387455035A5086569685 @default.
• W4387455035 hasAuthorship W4387455035A5087271386 @default.
• W4387455035 hasBestOaLocation W43874550351 @default.
• W4387455035 hasConcept C118552586 @default.
• W4387455035 hasConcept C126322002 @default.
• W4387455035 hasConcept C2776332859 @default.
• W4387455035 hasConcept C2776412080 @default.
• W4387455035 hasConcept C2779056891 @default.
• W4387455035 hasConcept C2779134260 @default.
• W4387455035 hasConcept C2779483572 @default.
• W4387455035 hasConcept C2779484449 @default.
• W4387455035 hasConcept C2780494398 @default.
• W4387455035 hasConcept C2780904820 @default.
• W4387455035 hasConcept C502032728 @default.
• W4387455035 hasConcept C71924100 @default.
• W4387455035 hasConcept C98274493 @default.
• W4387455035 hasConceptScore W4387455035C118552586 @default.
• W4387455035 hasConceptScore W4387455035C126322002 @default.
• W4387455035 hasConceptScore W4387455035C2776332859 @default.
• W4387455035 hasConceptScore W4387455035C2776412080 @default.

• next